德寶集團控股(08436.HK)年度純利1840.9萬港元 同比減少44.3%
格隆匯 3 月 19日丨德寶集團控股(08436.HK)公佈,截至2020年12月31日止年度,公司實現收益2.88億港元,同比增長8%; 股東應占盈利1840.9萬港元,同比減少44.3%;基本及攤薄每股盈利4.6港仙。
展望未來,董事認為,由於2019新型冠狀病毒爆發可能仍會持續一段時間,全球業務仍將不確定且充滿挑戰。公司將高度關注不斷變化的市場偏好,評估不同的銷售及營銷策略,並推出不同的新產品以滿足客户的需求。與往年一樣,集團的明確目標是鞏固其作為美容產品製造商及化粧袋解決方案提供商的地位。憑藉其競爭優勢,集團有信心可以克服挑戰併為股東保持可持續的業務表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.